Empagliflozin as a part of optimal medical therapy for chronic heart failure
This review is devoted to the role of sodium-glucose cotransporter type 2 (SGLT2) inhibitor empagliflozin in the treatment of chronic heart failure (CHF) with reduced left ventricular ejection fraction affecting the prognosis of disease. The results of clinical studies and additional analyses regarding the use of empagliflozin in various clinical situations are presented. Safety and laboratory changes following empagliflozin therapy are described. The author discusses the impact of empagliflozin on efficacy of other drugs for the treatment of CHF. Sequence of optimal medical therapy in CHF and advantages of early prescription of empagliflozin are also considered.